Stem Cell Transplant Complications Clinical Trial
Official title:
Tocilizumab for Cytokine Release Syndrome Prophylaxis in Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide
Tocilizumab will be administered prior to transplantation in order to prevent the onset of cytokine release syndrome and its complications associated to peripheral blood haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide
Cytokine release syndrome (CRS) is a common and potentially severe toxicity associated to haploidentical peripheral blood (PBSC) hematopoietic stem cell transplantation (Haplo-HSCT), which was described previously in the context of immunotherapies for acute lymphoblastic leukemia such as chimeric antigen receptor T-cells and blinatumomab. CRS is characterized by immune system activation with a high level of circulating inflammatory cytokines including IL-6. Haplo-HSCT recipients have a high incidence of post-transplant fever, with elevated IL-6 in absence of documented infection. CRS occurs more frequently when using PBSC, and severe cases have been associated to delayed engraftment, increased transplant-related mortality and lower survival. Tocilizumab an IL-6 receptor-targeted monoclonal antibody has been effectively used to treat CRS in several scenarios, including Haplo-HSCT. Therefore, there is considerable interest for the development of a successful strategy for CRS prevention with tocilizumab, potentially eliminating complications. However, it is currently unknown whether the use of this monoclonal antibody can adversely affect the outcome of Haplo-HSCT recipients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03482154 -
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
|
||
| Recruiting |
NCT06080490 -
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
|
||
| Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
| Recruiting |
NCT03871296 -
DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
|
||
| Not yet recruiting |
NCT06022445 -
Prospective Validation of CARPET Prognostic Model for Septic Shock After Allo-HSCT
|
||
| Recruiting |
NCT04502628 -
Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT
|
N/A | |
| Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
| Completed |
NCT03454568 -
The Patients' Experience After Stem Cell Transplant
|
||
| Recruiting |
NCT05466201 -
The Use of Eltrombopag Post HSCT in BMFS
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04080622 -
Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.
|
Phase 3 | |
| Recruiting |
NCT05523336 -
Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
|
||
| Completed |
NCT03355235 -
Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
|
||
| Completed |
NCT04888286 -
DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
|
||
| Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
| Active, not recruiting |
NCT03967665 -
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
|
Phase 3 | |
| Withdrawn |
NCT05104268 -
Study of a New Medical Device for Oral Mucositis
|
Early Phase 1 | |
| Recruiting |
NCT04623424 -
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
|
||
| Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
| Completed |
NCT03489551 -
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
|
Phase 4 | |
| Completed |
NCT04106089 -
Sleep in Pediatric HSCT
|
N/A |